According to a report by the Washington Post on Monday, the US FDA is expected to issue a new warning against Johnson & Johnson’s COVID-19 vaccine, linking it to a rare autoimmune disease.
The Washington Post quoted four people familiar with the matter on Monday as saying that the U.S. Food and Drug Administration (FDA) is preparing to issue a new warning against Johnson & Johnson’s COVID-19 vaccine, linking it to a rare autoimmune disease .
The Centers for Disease Control and Prevention (CDC) said in a statement on Monday that 12.8 million doses of Johnson & Johnson’s (J&J) COVID-19 jab was in the United States.
Most rare cases occur in people 50 years and older, usually two weeks after vaccination.
In the United States, approximately 3,000 to 6,000 people develop Guillain-Barré syndrome each year. This disease, which is not fully understood, is usually caused by a viral or bacterial infection.
According to the Washington Post, the increase in Guillain-Barré syndrome cases was related to swine flu vaccination in the 1970s.
A new warning will be the latest blow to Johnson & Johnson’s COVID vaccine-it only requires one injection and is easier to store than the two-dose mRNA vaccine developed by Moderna and Pfizer/BioNTech.
In April of this year, the US CDC and the FDA called for the suspension of the use of Johnson & Johnson’s COVID-19 vaccine because it was related to a rare case of severe thrombosis, but the temporary suspension was cancelled after it was determined that the benefits of the vaccine outweigh the risks.
Johnson & Johnson’s (J&J) COVID-19 vaccine also encountered production problems earlier this year, resulting in 75 million doses of vaccine being discarded.
European regulators have also issued similar warnings that AstraZeneca’s COVID-19 vaccine may increase the risk of Guillain-Barré syndrome.